CPRX
CPRX clinical trials: CATALYST PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where CATALYST PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 13
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CPRX on the catalyst calendar · CPRX registry changes
- Primary completion Feb 2032Sponsor estimateNo phase registeredNCT06564974Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMITCatalyst Pharmaceuticals, Inc. · Duchenne Muscular DystrophyRecruitingCPRXLeadICLRCollaboratorMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT02189720Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic SyndromeCatalyst Pharmaceuticals, Inc. · Congenital Myasthenic SyndromeApproved for marketingCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 5, 2022ActualPhase 3NCT03579966Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)Catalyst Pharmaceuticals, Inc. · Myasthenia Gravis, MuSKTerminatedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2020ActualPhase 3NCT03304054Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MGCatalyst Pharmaceuticals, Inc. · Myasthenia Gravis, GeneralizedCompletedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2021ActualPhase 2NCT03819660Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3Catalyst Pharmaceuticals, Inc. · Spinal Muscular Atrophy Type 3TerminatedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2020ActualPhase 2NCT03781479Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 PatientsCatalyst Pharmaceuticals, Inc. · Muscular Atrophy, SpinalCompletedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2012ActualPhase 1NCT01493596A Safety, Tolerability and Pharmacokinetic Study of CPP-115Catalyst Pharmaceuticals, Inc. · Cocaine DependencyCompletedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2019ActualPhase 3NCT02562066Amifampridine Phosphate for the Treatment of Congenital Myasthenic SyndromesCatalyst Pharmaceuticals, Inc. · Myasthenic Syndromes, CongenitalCompletedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2009ActualPhase 2NCT00730522Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine DependenceCatalyst Pharmaceuticals, Inc. · Methamphetamine DependenceTerminatedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2017ActualPhase 3NCT02970162Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)Catalyst Pharmaceuticals, Inc. · Lambert-Eaton Myasthenic SyndromeCompletedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualPhase 3NCT01377922A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)Catalyst Pharmaceuticals, Inc. · Lambert Eaton Myasthenic SyndromeCompletedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2012ActualPhase 2/Phase 3NCT01281202Vigabatrin for the Treatment of Cocaine DependencyCatalyst Pharmaceuticals, Inc. · Cocaine AddictionCompletedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2009ActualPhase 2NCT00611130Vigabatrin for Treatment of Cocaine DependenceCatalyst Pharmaceuticals, Inc. · Cocaine DependenceCompletedCPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 1NCT07470853A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.Whitehawk Therapeutics, Inc. · PROCRecruitingWHWKLeadCPRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimateNo phase registeredNCT02660645Blue Light Cystoscopy With Cysview® RegistryPhotocure · Bladder CancerRecruitingCPRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 25, 2019ActualNo phase registeredNCT04019795Modulated Light Therapy in Participants With Pattern Hair LossPhotonMD, Inc · Androgenetic AlopeciaCompletedCPRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03062631Treatment Use of 3,4 Diaminopyridine in Congenital MyastheniaRicardo Maselli · Congenital Myasthenic SyndromeNo longer availableCPRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2007ActualPhase 2NCT00527683Double Blind Study of Vigabatrin for the Treatment of Cocaine DependenceNYU Langone Health · Cocaine DependenceCompletedCPRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner